3 Quick Conclusions on a Dropped Biosimilar at Momenta Pharmaceuticals - Motley Fool

20-12-2013 Motley FoolComments (0)

Baxter InternationalOncologyPharmaceutical

On December 19, Baxter International (NYSE: BAX ) notified Momenta Pharmaceuticals (NASDAQ: MNTA ) that it was no longer interested in developing M511, a monoclonal antibody biosimilar for cancer, under a collaboration formed two years ago.

Read more on Motley Fool

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top